Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial

類似資料

• PD-004 Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study
  著者:: Marmorino, F., 等
  出版事項: (2016)
• The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)
  著者:: He K, 等
  出版事項: (2012-04-01)
• The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)
  著者:: He, Kuifeng, 等
  出版事項: (2012)
• First-line bevacizumab and capecitabine–oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study
  著者:: Feliu, J, 等
  出版事項: (2014)
• Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial
  著者:: Schirripa, Marta, 等
  出版事項: (2017)